Abstract 100: Somatic mutations in Pyk2 in melanoma alter protein activity, interactions and localization

Data indicates that focal adhesion kinases (FAKs) play a critical role in cancer. Specifically, accumulating evidence suggests that overexpression and altered activity of FAKs promotes tumorigenesis, metastasis, and correlates with reduced survival. Proline-rich tyrosine kinase 2 (PYK2, FAK2) and it...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2012-04, Vol.72 (8_Supplement), p.100-100
Hauptverfasser: Willard, Melinda D., Wulur, Isabella H., Samuels, Yardena, Barber, Thomas D., Gartner, Jared, Parker, Stephen C.J.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Data indicates that focal adhesion kinases (FAKs) play a critical role in cancer. Specifically, accumulating evidence suggests that overexpression and altered activity of FAKs promotes tumorigenesis, metastasis, and correlates with reduced survival. Proline-rich tyrosine kinase 2 (PYK2, FAK2) and its role in physiological processes in bone and inflammatory cellular responses have been well-documented. Recently, the role of PYK2 in the induction of endothelial to mesenchymal transition and cancer progression has emerged. Somatic mutations altering the coding region of PTK2B have been detected in melanoma and lung cancer, but the functional significance of these mutations is unknown. Here we demonstrate that cancer-associated mutations of PYK2 found in malignant melanoma lead to altered protein localization, interactions, and activity, and consequently, abnormal cellular behavior. These findings suggest that somatic mutations in PTK2B may promote tumor progression through deregulated protein activity, and highlight the importance of evaluating PYK2 inhibitors to block both the normal and mutant forms of the kinase. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 100. doi:1538-7445.AM2012-100
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2012-100